Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 298 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizo-Affective Type of Psychosis Clear all
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

NCT00139906
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 26, 2026, 2:27 AM EDT
Recruiting Phase 4 Interventional

Exercise and Olanzapine-samidorphan

NCT06740890
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions
Olanzapine-samidorphan + exercise
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 26, 2026, 2:27 AM EDT
Recruiting Phase 4 Interventional

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

NCT05208190
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Clozapine, treatment as usual
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

NCT00634348
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
41
States / cities
Anaheim, California • Cerritos, California • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 26, 2026, 2:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 26, 2026, 2:27 AM EDT
Suspended Phase 1Phase 2 Interventional

D-serine AudRem: R33 Phase

NCT05046353
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
D-serine, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View directory record Official record
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 26, 2026, 2:27 AM EDT
Completed No phase listed Observational

Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

NCT01786369
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

NCT01394471
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Intranasal Oxytocin Spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

NCT00061802
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
risperidone, quetiapine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Early Phase 1 Interventional

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

NCT01519557
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DAR-100A, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCT02237235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
MMFS-202-302, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT02658357
View directory record Official record
Conditions
Schizophrenia, Schizo-affective Disorder
Interventions
Risperidone Implant
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)

NCT00119574
View directory record Official record
Conditions
Schizophrenia Disorders, Chronic Illness, Schizoaffective Disorder, Weight Gain
Interventions
Collaborative Chronic Illness Model
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Probiotics to Prevent Relapse After Hospitalization for Mania

NCT01731171
View directory record Official record
Conditions
Bipolar Disorder, Schizoaffective Disorder
Interventions
Probiotic Supplement, Inert Compound
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 26, 2026, 2:27 AM EDT
Terminated Not applicable Interventional Results available

Repetitive TMS & Cognitive Training in Adults With Schizophrenia

NCT03741751
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Cognitive Impairment
Interventions
rTMS, Computerized cognitive training
Device · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

NCT00330551
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

NCT00793780
View directory record Official record
Conditions
Obesity, Schizophrenia, Schizoaffective Disorder
Interventions
Naltrexone 25mg, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Results available

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

NCT02188121
View directory record Official record
Conditions
Serious Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Cardiovascular Disease, Major Depressive Disorder, Psychosis NOS
Interventions
Simvastatin, Losartan
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness

NCT03208036
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizo Affective Disorder
Interventions
TDCS, Sham Stimulation, Cognitive Remediation, Bridging Group
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 2Phase 3 Interventional

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Sulforaphane to Reduce Symptoms of Schizophrenia

NCT02810964
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sulforaphane Nutraceutical, Identical-appearing Placebo
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies

NCT05127837
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depressive Disorder
Interventions
CBTpro
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Morgan Hill, California • San Jose, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 26, 2026, 2:27 AM EDT